Ansa Biotechnologies
Next-generation DNA synthesis using enzymes
About Ansa Biotechnologies
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.
Company details
Funding
Total raised
$130.3M
Last stage
Series B
Investors
Founders
Sebastian Palluk
PhD researcher at JBEI who partnered with Lin-Arlow to develop the first enzymatic de novo DNA synthesis method. As CTO, leads continued technology advancement and platform development. Co-inventor on 11 patent families.
Daniel Lin-Arlow
PhD from UC Berkeley (Jay Keasling lab). Co-invented the first practical enzymatic de novo DNA synthesis method at Lawrence Berkeley National Laboratory's JBEI. Served as founding CEO from 2018 to 2024, then transitioned to CSO.
LinkedInJared Ellefson
Focused on directed evolution of novel polymerase enzymes; joined as the third co-founder after Lin-Arlow and Palluk's 2018 Nature Biotechnology publication.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.